Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP4K4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP4K4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP4K4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP4K4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP4K4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAP4K4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP4K4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000167817 | Oral cavity | EOLP | cellular glucose homeostasis | 36/2218 | 172/18723 | 4.51e-04 | 3.98e-03 | 36 |
GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
GO:0034284110 | Oral cavity | EOLP | response to monosaccharide | 44/2218 | 225/18723 | 5.38e-04 | 4.63e-03 | 44 |
GO:0009746110 | Oral cavity | EOLP | response to hexose | 43/2218 | 219/18723 | 5.67e-04 | 4.81e-03 | 43 |
GO:007030224 | Oral cavity | EOLP | regulation of stress-activated protein kinase signaling cascade | 39/2218 | 195/18723 | 6.89e-04 | 5.70e-03 | 39 |
GO:00518947 | Oral cavity | EOLP | positive regulation of focal adhesion assembly | 10/2218 | 28/18723 | 9.28e-04 | 7.08e-03 | 10 |
GO:00435479 | Oral cavity | EOLP | positive regulation of GTPase activity | 47/2218 | 255/18723 | 1.34e-03 | 9.33e-03 | 47 |
GO:007133317 | Oral cavity | EOLP | cellular response to glucose stimulus | 31/2218 | 151/18723 | 1.50e-03 | 1.01e-02 | 31 |
GO:19018889 | Oral cavity | EOLP | regulation of cell junction assembly | 39/2218 | 204/18723 | 1.67e-03 | 1.11e-02 | 39 |
GO:003287224 | Oral cavity | EOLP | regulation of stress-activated MAPK cascade | 37/2218 | 192/18723 | 1.87e-03 | 1.21e-02 | 37 |
GO:007133117 | Oral cavity | EOLP | cellular response to hexose stimulus | 31/2218 | 153/18723 | 1.87e-03 | 1.21e-02 | 31 |
GO:000974918 | Oral cavity | EOLP | response to glucose | 40/2218 | 212/18723 | 1.89e-03 | 1.21e-02 | 40 |
GO:007132617 | Oral cavity | EOLP | cellular response to monosaccharide stimulus | 31/2218 | 154/18723 | 2.08e-03 | 1.32e-02 | 31 |
GO:007132218 | Oral cavity | EOLP | cellular response to carbohydrate stimulus | 32/2218 | 163/18723 | 2.70e-03 | 1.62e-02 | 32 |
GO:004259317 | Oral cavity | EOLP | glucose homeostasis | 46/2218 | 258/18723 | 2.96e-03 | 1.74e-02 | 46 |
GO:003350017 | Oral cavity | EOLP | carbohydrate homeostasis | 46/2218 | 259/18723 | 3.20e-03 | 1.86e-02 | 46 |
GO:004632814 | Oral cavity | EOLP | regulation of JNK cascade | 27/2218 | 133/18723 | 3.44e-03 | 1.98e-02 | 27 |
GO:00311021 | Oral cavity | EOLP | neuron projection regeneration | 15/2218 | 60/18723 | 3.58e-03 | 2.03e-02 | 15 |
GO:00705701 | Oral cavity | EOLP | regulation of neuron projection regeneration | 10/2218 | 33/18723 | 3.76e-03 | 2.10e-02 | 10 |
GO:01501177 | Oral cavity | EOLP | positive regulation of cell-substrate junction organization | 10/2218 | 33/18723 | 3.76e-03 | 2.10e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4K4 | SNV | Missense_Mutation | | c.3526N>T | p.Val1176Phe | p.V1176F | | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.98) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.3715N>C | p.Phe1239Leu | p.F1239L | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP4K4 | SNV | Missense_Mutation | | c.451N>T | p.His151Tyr | p.H151Y | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.643N>A | p.Asp215Asn | p.D215N | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.1246G>C | p.Glu416Gln | p.E416Q | | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.888) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.592N>A | p.Glu198Lys | p.E198K | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.673N>C | p.Glu225Gln | p.E225Q | | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.2322N>C | p.Leu774Phe | p.L774F | | protein_coding | tolerated_low_confidence(0.59) | probably_damaging(0.991) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.2741N>C | p.Gly914Ala | p.G914A | | protein_coding | tolerated_low_confidence(0.39) | probably_damaging(0.997) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP4K4 | insertion | Nonsense_Mutation | novel | c.1598_1599insGGAGGGTCAGACATAGACACAAGAGACGTAGAT | p.Asp533delinsGluGluGlyGlnThrTerThrGlnGluThrTerIle | p.D533delinsEEGQT*TQET*I | | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CYC-116 | CYC-116 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PAZOPANIB | PAZOPANIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | AST-487 | AST-487 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PD-0166285 | PD-0166285 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SB-220025 | SB-220025 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CEDIRANIB | CEDIRANIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | OSI-632 | OSI-632 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | AZD-1152-HQPA | AZD-1152-HQPA | |